Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Total Liabilities
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has total liabilities worth $5.30 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sagimet Biosciences Inc. Series A Common Stock - Total Liabilities Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Sagimet Biosciences Inc. Series A Common to evaluate short-term liquidity relative to the company's equity base.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Total Liabilities
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AbClon Inc
KQ:174900
|
Korea | ₩9.44 Billion |
|
Orion Engineered Carbons SA
NYSE:OEC
|
USA | $1.55 Billion |
|
Aurora Corp
TW:2373
|
Taiwan | NT$9.26 Billion |
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
China | CN¥1.64 Billion |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
USA | $309.79 Million |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452
|
China | CN¥635.27 Million |
|
Key Ware Electronics Co Ltd
TWO:5498
|
Taiwan | NT$1.75 Billion |
|
Wuhan Nusun Landscape Co Ltd
SHE:300536
|
China | CN¥459.15 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Sagimet Biosciences Inc. Series A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sagimet Biosciences Inc. Series A Common (SGMT) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sagimet Biosciences Inc. Series A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual total liabilities of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.10 Million | +14.53% |
| 2024-12-31 | $4.45 Million | -21.22% |
| 2023-12-31 | $5.65 Million | -97.43% |
| 2022-12-31 | $219.98 Million | +1.24% |
| 2021-12-31 | $217.29 Million | +6.06% |
| 2020-12-31 | $204.87 Million | +50.11% |
| 2019-12-31 | $136.47 Million | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more